AFFECTIVE INSTABILITY AND PROTEIN KINASE C SIGNAL TRANSDUCTION PATHWAYS

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。该研究的主要目的是确定人格障碍患者的情感不稳定性（A1）是否与血小板蛋白激酶C（PKC）活性水平相关，该活性水平不同于健康对照组和无情感不稳定性的人格障碍患者。次要目的是确定丙戊酸盐或奥氮平治疗情感不稳定的人格障碍患者是否会使PKC活性正常化，以及这种正常化的程度是否与症状改善相关。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective of the proposed study is to determine whether the trait of affective instability (A1) in patients with personality disorders is associated with levels of platelet protein kinase C (PKC) activity which differ from that seen in healthy controls and in personality disorder patients without affective instability. The secondary objective is to determine whether treatment of personality disorder patients who have affective instability with valproate or olanzepine will normalize PKC activity and whether the degree of this normalization correlates with symptomatic improvement.